Engineered Leucine Decarboxylase for Stable Low-pH BCAA Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for maple syrup urine disease (MSUD) and related disorders of leucine metabolism, such as isovaleric acidemia and 3-methylcrotonylglycinuria, are inadequate in managing elevated levels of branched-chain amino acids (BCAAs) due to insufficient enzyme activity and stability, leading to neurological issues and metabolic complications.
Innovation Solution
Engineered leucine decarboxylase (LDC) polypeptides with enhanced catalytic activity, stability, and tolerance to low pH environments are developed, along with recombinant polynucleotides encoding these polypeptides, to reduce plasma levels of leucine, isoleucine, and related metabolites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type leucine decarboxylase is used, then the enzyme can catalyze leucine metabolism, but the enzyme activity is insufficient and stability is poor, leading to inadequate management of elevated BCAA levels
Solution Approach 1:
The patent applies parameter changes by modifying amino acid residues at specific positions (e.g., E122Q, E122A, E122K, E122R substitutions) to alter the enzyme's physical and chemical properties. These substitutions change the local charge environment and hydrogen bonding networks, thereby improving both stability and catalytic activity simultaneously
Solution Approach 2:
The patent creates composite enzyme structures by combining wild-type LDC with engineered variants or forming complexes with stabilizing proteins. The engineered LDC variants themselves represent composite structures where specific amino acid modifications create new functional properties that combine stability and activity
2Stability of the object's composition
If the enzyme is engineered for enhanced stability, then storage stability improves, but the complexity of enzyme production increases
Solution Approach 1:
The patent applies preliminary action by pre-engineering the LDC enzyme with stabilizing mutations before clinical use. The enzyme is produced in advance with built-in stability features (disulfide bonds, surface charge modifications) that ensure long-term stability during storage and transport, eliminating the need for complex cold chain logistics
Solution Approach 2:
The patent enables the use of engineered LDC as a stable, long-lasting therapeutic that can be produced once and stored for extended periods. The enzyme replacement therapy approach allows for periodic administration rather than continuous infusion, reducing the complexity of ongoing treatment logistics
3Reliability
If conventional treatments with protein restriction are used, then toxic amino acid levels can be managed, but the diet becomes highly restrictive and quality of life decreases
Solution Approach 1:
The patent introduces engineered LDC as an intermediary enzyme that compensates for the defective BCKDH complex. This exogenous enzyme acts as a mediator to degrade toxic BCAAs, allowing patients to maintain normal protein intake while achieving metabolic control, thus eliminating the need for restrictive diets
4Adaptability or versatility
If the enzyme tolerance to low pH is improved, then the enzyme can function in acidic environments, but the complexity of enzyme engineering increases
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions (e.g., E122Q, E122A) that modify the enzyme's charge distribution and hydrogen bonding capacity. These changes enhance the enzyme's ability to maintain structural integrity and catalytic function in acidic environments without requiring complex multi-domain engineering
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered LDC polypeptides effectively lower toxic amino acid levels, ameliorating symptoms of MSUD and related disorders, allowing for less restrictive diets and improved patient outcomes.
Implementation Method 1
engineered leucine decarboxylase (LDC) polypeptides... to reduce plasma levels of leucine, isoleucine, and related metabolites
Data Source
AI summary
The present invention provides engineered leucine decarboxylase (LDC) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered leucine decarboxylase polypeptides. In some embodiments, the engineered leucine decarboxylase polypeptides display enhanced catalytic activity, as well as reduced sensitivity to proteolysis, and/or increased tolerance to low pH environments. In some embodiments, the engineered leucine decarboxylase polypeptides are optimized to provide improved storage stability. The present invention also provides methods for the use of the compositions comprising the engineered leucine decarboxylase polypeptides for therapeutic and industrial purposes.